Gadget Galiyara

Humoral immune response to SARS-CoV2 in Iceland

Image default

Titers of antibodies against SARS-CoV2 do not decline within four months

REYKJAVIK, Iceland, Sept. 1, 2020 /PRNewswire/ — Scientists at deCODE genetics in Iceland, a subsidiary of Amgen Inc , biopharmaceutical company headquartered in California, and their collaborators, today publish a study in The New England Journal of Medicine, that shows that antiviral antibodies against SARS-CoV2 do not decline within four months of diagnosis.

The aim of the study was to obtain understanding of the nature and durability of the humoral immune response to infection by SARS-CoV-2, the virus that causes COVID-19.

To that end the scientists measured antibodies in the sera of 30,576 persons in Iceland (8.4% of the nation) using six assays (two of them pan-Ig) and determined that the best measure of seropositivity was a positive result with both pan-Ig assays. They tested 2.102 samples from 1,237 qPCR-positive persons obtained up to 4 months from diagnosis. They also measured antibodies in 4,222 samples from exposed, quarantined persons and 19000 persons not known to have been exposed.

Of quarantined persons, 2.3% were seropositive and of those with unknown exposure, 0.3% were positive.

The scientists estimate that 0.9% of Icelanders were infected by SARS-CoV-2 and 44% of people infected with SARS-CoV2 in Iceland were not diagnosed with qPCR. The infection fatality rate is 0.3%.  Of the 1,797 persons who recovered from SARS-CoV-2  in Iceland, 1,107 (91.1%) were seropositive.

“We are pleased to be able to put to rest the concern that the titer of the antiviral antibodies may decline within weeks of infection, says Kari Stefansson, CEO of deCODE genetics and senior author on the paper. Furthermore it is clear that 99,1% of Icelanders are still vulnerable to SARS-CoV2. We are now focused on studying cell mediated immunity in those who do not raise antibodies.”

Based in Reykjavik, Iceland, deCODE is a global leader in analyzing and understanding the human genome. Using its unique expertise in human genetics combined with growing expertise in transcriptomics and population proteomics and vast amount of phenotypic data, deCODE has discovered risk factors for dozens of common diseases and provided key insights into their pathogenesis. The purpose of understanding the genetics of disease is to use that information to create new means of diagnosing, treating and preventing disease. deCODE is a wholly-owned subsidiary of Amgen (NASDAQ:AMGN).

Video – https://mma.prnewswire.com/media/1245576/Kari_and_Daniel_on_Covid_19_paper.mp4  

Logo – https://gadgetgaliyara.com/wp-content/uploads/sites/4/2020/09/Humoral-immune-response-to-SARS-CoV2-in-Iceland.jpg

 

Contact:

Thora Kristin Asgeirsdottir

PR and Communications

deCODE genetics

thoraa@decode.is 

354 894 1909

 

This story has been sourced from a third party syndicated feed, agencies. Gadget Galiyara accepts no responsibility or liability for its dependability, trustworthiness, reliability, and data of the text. DigitalGaliyara (OPC) Private Limited management reserves the sole right to alter, delete, or remove (without notice). If you have any concerns with the Content, then please write to us at the mail@digitalgaliyara.com

Source link

Follow us on Social Media or follow us on Google News FacebookInstagram, and Twitter.

For Videos Content and Stories subscribe to our YouTube Channel.

Gadget Galiyara is now on Telegram. Click here to join our channel (gadgetgaliyara) and stay updated with the latest news

Related posts

Leave a Comment

* By using this form you agree with the storage and handling of your data by this website.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More